Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    ONLINE TRAINING 2016 - Device Changes and the 510(k) - By AtoZ Compliance

    View: 330

    Website http://bit.ly/1XfFAj1 | Want to Edit it Edit Freely

    Category 510(k) training, fda 510 k, 510 k clearance, fda medical device approval , 510(k) submissions

    Deadline: March 15, 2016 | Date: March 15, 2016

    Venue/Country: New Hyde Park, U.S.A

    Updated: 2016-02-10 13:56:37 (GMT+9)

    Call For Papers - CFP

    Key Take Away

    Understand the approaches required for Medical Device product changes; if it’s a risk-based process and how to maximize the process against scarce resources giving different considerations for CE-marked products.

    Overview

    The FDA holds companies responsible for filing new 510(k) training when one change is major enough to impact safety / effectiveness, or when a series of lesser changes finally reach the "tipping point". This is a major headache. How can companies make that determination? How can they trigger such an analysis over the major change or the series of smaller changes?

    Why Should You Attend

    The majority of medical devices are cleared for marketing in the U.S. by the FDA 510(k) process.

    Areas Covered In This Webinar

    What approaches are required for product changes; for process changes? How is the process risk-based? How to maximize the process against scarce resources. What are the different considerations for CE-marked product?

    Learning Objectives

    U.S. FDA device clearance / approval

    FDA's and EU's emphasis

    Product changes and filing a new 510(k) clearance ? who's responsible

    Tracking and evaluating changes ? the "tipping point"

    Is the process "risk based"?

    K-97-1 and the FDA's medical device approval

    Documenting the process / rationale

    Resolving wrong 510(k) submissions

    Who Will Benefit

    Senior Management, Project Leaders, Internal / External Consultants

    Regulatory Affairs Personnel

    Quality Systems Personnel

    R&D and Engineering Staff

    Personnel involved in Lean and Six Sigma Initiatives

    CAPA Personnel

    Speakers Profile

    John E. Lincoln

    John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 33 years' experience in U.S. FDA regulated industries, 19 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D).

    In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. He writes a recurring column for the Journal of Validation Technology. John is a graduate of UCLA.

    For more detail please click on this below link:

    http://bit.ly/1XfFAj1

    Email: referralsatatozcompliance.com

    Toll Free: +1- 844-414-1400

    Tel: +1-516-900-5509


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.